Informazioni sul prodotto
- Bryostatin1, 35-demethoxy-22,35-epoxy-, (22S)-
- 5,27:9,13:15,19-Triepoxy-2H-furo[2,3-e]oxacyclohexacosin,bryostatin 1 deriv.
- 2,4-Octadienoic acid,17-(acetyloxy)-4,5,6,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,25,26,27,27a-docosahydro-5,15,21-trihydroxy-25-(1-hydroxyethyl)-11-(2-methoxy-2-oxoethylidene)-6,6,16,16-tetramethyl-2,23-dioxo-5,27:9,13:15,19-triepoxy-2H-furo[2,3-e]oxacyclohexacosin-4-ylester,[4S-[4R*(2E,4E),5R*,7E,9S*,11Z,13R*,15R*,17R*,19S*,21S*,25S*(S*),27S*,27aR*]]-
Bryostatin 3 is a polyunsaturated fatty acid that has been shown to be a potent anticancer agent. It inhibits the growth of cancer cells by activating protein kinase C and phospholipase C, which are enzymes that regulate membrane function. Bryostatin 3 also exhibits antimicrobial activity against Gram-positive bacteria and HIV. The molecule is synthesized by the asymmetric addition of a hydroxyl group to an organic quinoline derivative. The effective dose for bryostatin 3 is 10-30 ng/kg body weight per day, and it can be given intravenously or orally.
Proprietà chimiche
Richiesta tecnica su: 3D-TFA37084 Bryostatin 3
Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.
